Project Grant R43HG012858

Award Date 4/23/24

Completion Date 4/22/25

Dollars Obligated $347K

Federal Agency

National Human Genome Research Institute

Awardee

Electronic Biosciences, Inc. (FLHHE89XH2H5)

Federal Grant Program

93.172

Assistance Type

Project Grant

Place of Performance

Emigration Canyon, UT 84108, USA

Similar Awards

Project Grant R41GM157757
Electronic Biosciences, Inc. received a $350,000 Phase I Small Business Technology Transfer (STTR) project grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded on June 1, 2025, with a completion date of May 31, 2027. The company, in collaboration with Distinguished Professor Cynthia J. Burrows, is developing the first high-accuracy sequencing technology capable of simultaneously detecting...
Project Grant R43HG014419
Federal Grant Award Summary: SPINSEQ Project Electronic Biosciences, Inc. received a Phase I Small Business Innovation Research (SBIR) Project Grant of $383,482 from the National Human Genome Research Institute (NHGRI) under the Human Genome Research program (CFDA 93.172), awarded on June 6, 2025, with a completion date of May 31, 2027. The company is developing SPINSEQ, an innovative RNA sequencing platform designed to deliver precise and accurate transcriptomic analysis while preserving RNA...
Project Grant 2151149
This $256,000 National Science Foundation Engineering grant supports the development of an easy RNA adenylation method for deep sequencing of picogram RNA samples with high resolution. Specifically, Ezrabio Inc. will develop a versatile and cost-effective library construction technology that enables protein translation monitoring on a variety of biological samples. The proposed technology relies on a novel enzyme system capable of 5' adenylation and 3' polyadenylation of RNA fragments to...
Project Grant R43HG012170
The Alida Biosciences Inc. was awarded a $765,105 Project Grant from the National Institutes of Health National Human Genome Research Institute under the Human Genome Research federal grant program (CFDA 93.172) on August 17, 2021 to complete work by February 28, 2022. The grant funds the development of a new approach to analyze RNA modifications across entire transcriptomes in a multiplexed reaction at near single-base resolution. Currently available methods either lack sequence context or...
Project Grant 2330699
This $750,000 Project Grant award from the National Science Foundation's (NSF) Mathematical and Physical Sciences (CFDA 47.049) program supports the development of a novel platform to enable rapid and robust identification of functional RNA molecules directly within mammalian cellular environments. The research aims to solve the challenge of RNA structure sensitivity to local environments that has hindered progress in the field of functional RNA discovery. The project will deliver a customized...
Project Grant R43HG011608
Armonica Technologies, Inc. was awarded a $1,047,600 Project Grant from the National Human Genome Research Institute of the Department of Health and Human Services to develop a novel DNA sequencing platform. The award was made under the Human Genome Research program (CFDA 93.172), which supports technologies to accelerate genomic research and its application to human health. Specifically, Armonica will use the funding to optimize a metal-insulator-metal structure for single base sensitivity...
Project Grant R43HG011679
This Project Grant award from the National Institutes of Health's National Human Genome Research Institute provided $768,678 to Molecular Assemblies, Inc. to develop a fully enzymatic oligonucleotide synthesis cycle using engineered template-independent polymerases and a novel phosphate dNTP blocking group. The award supports the goals of the Human Genome Research program (CFDA 93.172) to accelerate genome research and its application to human health. Specifically, the awardee will engineer...
Project Grant 2421692
This $3,000,000 project grant, awarded by the National Science Foundation (NSF) under the Engineering (CFDA 47.041) program, aims to solve the long-standing challenge of developing self-amplifying ribonucleic acid (SARNA) technologies. The project, led by Trustees of Boston University, a private non-profit research university, will: Synthesize a diverse library of modified nucleoside triphosphates (ModNTPs) and use them to produce modified SARNA with extended cellular half-life. Evaluate the...
Project Grant R43GM151884
The National Institute of General Medical Sciences (NIGMS) awarded a $305,892 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to Dotquant LLC, a biotechnology research and development company, to develop a new in vitro transcription kit for high-yield synthesis of chemically modified RNA. The project aims to combine the benefits of wild-type T7 RNA polymerase, which has high efficiency and low cost, with the ability of mutant T7 RNA polymerases to...
Project Grant 2222688
Micropure Genomics Inc. received a $274,199 Project Grant award from the National Science Foundation to advance methods for rapid, end-to-end sample preparation for sequencing applications. Under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084), the company will develop an automated process relying on electro-hydrodynamic trapping to isolate genomic material like DNA or RNA from cells in a flow cartridge. The process aims to significantly reduce preparation time while...

RE-READING RNA TO OBTAIN HIGH ACCURACY - PROJECT SUMMARY THE ULTIMATE GOAL IN THE FIELD OF RNA SEQUENCING (TRANSCRIPTOMICS AND EPITRANSCRIPTOMICS) IS SINGLE-MOLECULE, HIGH-ACCURACY, DE NOVO RNA SEQUENCING, INCLUDING THE ABILITY TO SEQUENCE MODIFIED BASES WITHOUT THE NEED FOR ADDITIONAL TECHNIQUES/METHODS THAT ADD TIME, COST, AND SAMPLE REQUIREMENTS. UNFORTUNATELY, CURRENT TRANSCRIPTOMIC SEQUENCING TECHNOLOGIES ARE COSTLY, HAVE LOW ACCURACY (SPECIFICALLY RELATIVE TO DNA SEQUENCING APPROACHES), THEY CAN REQUIRE REVERSE TRANSCRIPTION THAT REMOVES THE IDENTITY OF MODIFIED BASES (LIMITING/PROHIBITING EPITRANSCRIPTOMIC INVESTIGATIONS), AND/OR THEY CAN USE OR REQUIRE PROCESSIVE ENZYMES THAT FAIL TO TRAVERSE CERTAIN TYPES OF SEQUENCES. DURING THIS PHASE I SBIR PROJECT, WE WILL DEVELOP A SEQUENCING TECHNOLOGY/METHODOLOGY THAT OVERCOMES THESE SHORT COMINGS, AND IS CAPABLE OF STATE-OF-THE-ART, RNA SEQUENCING AND CHARACTERIZATION. MORE SPECIFICALLY, WE WILL DEVELOP AND DEMONSTRATE AN APPROACH FOR CONTROLLABLY AND ITERATIVELY TRANSLOCATING SINGLE RNA MOLECULES BACK-AND-FORTH THROUGH A NANOPORE READER SUCH THAT SINGLE MOLECULES CAN BE DIRECTLY AND REPEATEDLY SEQUENCED, AND CORRESPONDING ULTRA-HIGH ACCURACY CONSENSUS SEQUENCE DETERMINATIONS CAN BE MADE. FURTHERMORE, DURING THIS PROJECT, WE WILL DEMONSTRATE THE ABILITY TO MULTIPLEX THE ASSOCIATED MEASUREMENT, SIGNIFICANTLY REDUCING THE RISK ASSOCIATED WITH DEVELOPING A HIGH- THROUGHPUT, SINGLE-MOLECULE SEQUENCING SYSTEM FOLLOWING THIS EFFORT. NANOPORE-BASED TECHNOLOGY HAS THE POTENTIAL TO ENABLE COMPLETE AND COMPREHENSIVE RNA SEQUENCING, AND TO BE A FIELD-LEADING TECHNOLOGY IN THE FUTURE. DURING THIS PROJECT, WE WILL TAKE STEPS TOWARD MAKING THAT FUTURE A REALITY BY DEVELOPING AND OPTIMIZING ALL COMPONENTS OF OUR TECHNOLOGY AND THEN DEMONSTRATING RNA SEQUENCING, INCLUDING THE ABILITY TO SEQUENCE N6- METHYLADENOSINE (M6A), 5-METHYLCYTOSINE (M5C), AND PSEUDOURIDINE (Ps). WE WILL THEN SHOW THE FUNCTIONALITY AND ADVANTAGES OF THE DEVELOPED TECHNOLOGY BY BENCHMARKING OUR APPROACH AGAINST CURRENT NANOPORE-BASED SEQUENCING APPROACHES.

Posted 4/23/24

Mod #	Description	ReasonForModification	Federal Obligation	Date
Not listed			$347.0k	4/23/24